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UbiquitinTRIM8 is a member of a protein family deﬁned by the presence of a common domain structure composed of a
tripartite motif including a RING-ﬁnger, one or two B-box domains and a coiled-coil motif. Here, we show that
TRIM8 interacts with Hsp90β, which interacts with STAT3 and selectively downregulates transcription of
Nanog in embryonic stem cells. Knock-down of TRIM8 increased phosphorylated STAT3 in the nucleus and
also enhanced transcription of Nanog. These ﬁndings suggest that TRIM8 modulates translocation of
phosphorylated STAT3 into the nucleus through interaction with Hsp90β and consequently regulates
transcription of Nanog in embryonic stem cells.mistry, Hokkaido University
Sapporo, Hokkaido 060-8638,
yama).
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Ubiquitin-mediated proteolysis plays an important role in the
elimination of short-lived proteins [1], including those that contribute
to the cell cycle, cellular signaling in response to environmental stress
or extracellular ligands, morphogenesis, secretion, DNA repair, and
organelle biogenesis [2,3]. This pathway includes two key steps:
covalent attachment of multiple ubiquitin molecules to the protein
substrate and degradation of the ubiquitinated protein by the 26S
proteasome complex. The system responsible for the attachment of
ubiquitin to the target protein consists of several components that act
in concert [4,5], including a ubiquitin-activating enzyme (E1), a
ubiquitin-conjugating enzyme (E2), and a ubiquitin–protein isopep-
tide ligase (E3). E3 is thought to be the component of the ubiquitin
conjugation system that is most directly responsible for substrate
recognition [5,6]. On the basis of structural similarity, E3 enzymes
have been classiﬁed into three families: HECT (homologous to E6-AP
COOH terminus) family [3,7], U-box family [8–10] and RING ﬁnger-
containing protein family [11–13].The superfamily of tripartite motif-containing (TRIM) proteins is
deﬁned by the presence of a tripartite motif composed of a RING
domain, one or two B-box motifs and a coiled-coil region (so-called
RBCC motif) [14,15]. The conservation of these domains in TRIM
proteins from various species indicates that the RBCC motif is the
deﬁning characteristic of this superfamily. TRIM proteins are
conserved throughout the metazoan kingdom and have expanded
rapidly during vertebrate evolution [16]. There are nowmore than 70
known TRIM proteins in humans and mice. Many TRIM proteins are
induced by type I and type II interferons (IFNs), suggesting that TRIM
proteins play an important role in anti-viral and anti-microbial
systems [17].
It has been reported that TRIM8 is expressed in various human
tissues, including the brain, lung, breast, gut, placenta, kidney, muscle
and germinal center B cells [18,19]. TRIM8 contains an N-terminal
RING ﬁnger, followed by two B-boxes and a coiled-coil domain, and
thus belongs to the TRIM/RBCC family. It has been reported that
TRIM8 localized to speciﬁc nuclear bodies and cytosolic speckles in
U2OS and HeLa cells [19,20]. TRIM8 has been identiﬁed as a
suppressor of cytokine signaling (SOCS)-1-interacting protein [21].
It has been reported that TRIM8 mRNA can be induced by IFN-γ in
murine B lymphoid M12 cells, murine ﬁbroblasts and HeLa cells and
that amino-terminal 204 amino acids of TRIM8 accelerate the
degradation of SOCS-1 and reverse SOCS-1-mediated inhibition of
Janus kinase (JAK)-STAT activation by IFN-γ [21]. However, it is not
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pathway. We have recently reported that TRIM8 interacts with and
inhibits the function of the protein inhibitor of activated STAT3
(PIAS3) [20]. It has been reported that PIAS3 inhibits DNA-binding
activity of STAT3, followed by the suppression of STAT3-mediated
gene activation [22]. Since many cytokine receptors do not have
intrinsic tyrosine-kinase activity, ligand engagement leads to the
activation of receptor-associated tyrosine kinases, which are usually
members of the JAK family [23–26].
STAT3 has been shown to play an important role in the signaling
pathway dependent on leukemia inhibitory factor (LIF) in ES cells to
maintain a pluripotent state [27]. Recently, it has been shown that LIF-
dependent signaling pathways in mouse ES cells consist of two parallel
pathways [28]. In brief, the JAK-STAT3 pathway and the phosphatydy-
linositol-3-phosphate (PI3) kinase-Akt pathway regulate Klf4 and Tbx3,
respectively. Klf4 mainly regulates Sox2, whereas Tbx3 mainly
regulates Nanog [28]. Transfection of Tbx3 or Klf4 into the CCE-derived
MGZ5 ES cell line using an integrated copy of the transgene resulted in
the formation of LIF-independent clones [28]. However, no stable
transfectants were recovered when MGZ5 ES cells were transfected
with Tbx3 and Klf4 using an episomal vector system that confers a
high expression level of the transgene, indicating a tight dosage effect
of these genes [27]. Tbx3, Klf4 and Nanog were heterogeneously
expressed in ES cells and were not always coordinated, although 24% of
the cellswere triple-positive [28]. Theseﬁndings clearly indicate that ES
cells are not simply regulated by LIF in a conventional culture condition
but are also modulated by other signals. In contrast, Oct3/4 expression
was quite homogeneous [28,29], indicating that the ﬂuctuating
expression of upstream transcription factors converged to a constant
expression of Oct3/4, maintaining a steady state of self-renewal [28].
However, it has not been clariﬁed how upstream ﬂuctuating signals are
controlled as a constant signal to Oct3/4.
In this study, we showed that TRIM8 binds to Hsp90β in mouse ES
cells. Hsp90β has been shown to interact with STAT3 and to accelerate
nuclear translocation of STAT3 in mouse ES cells [30]. Knock-down of
TRIM8 in mouse ES cells resulted in accumulation of tyrosine 705
(Y705)-phosphorylated STAT3 in the nucleus and also resulted in up-
regulation of transcription of Nanog, suggesting that TRIM8 has an
important role in the regulation of STAT3-mediated signaling in ES
cells.
2. Materials and methods
2.1. Plasmid construction
FLAG–TRIM8(WT or ΔRING) and HA-TRIM8(WT or ΔRING) were
described previously [20]. TRIM8 cDNAwas ligated into EcoR I and Sal I
sites of pET30a (Merck, Whitehouse Station, NJ) or pMAL-c2 (New
England BioLab, Ipswich, MA). pSUPER-retro-puro (OligoEngine,
Seattle, WA) was utilized for knock-down of TRIM8. pSUPER-retro-
puro containing a nonfunctional random sequence or TRIM8 sequences
(#2: 5′-GAACACCAAGTCTGTGAAA-3′, and #5: 5′-GATTCTCGTCTGTTC
TGTG-3′) was constructed according to the manufacturer′s protocol.
2.2. Reagents
Cycloheximide, cisplatin, etoposide, retinoic acid, trichloroacetic
acid, anti-FLAG-M2 agarose, FLAG peptide and protein G sepharose
were purchased from Sigma (St. Louis, MO). Protein A sepharose (GE
Healthcare Bioscience, Piscataway, NJ, USA) and DMP (ThermoFisher,
Waltham,MA, USA)were purchased from the indicatedmanufacturers.
2.3. Cell culture and transfection
293T and HeLa cells were cultured as described previously [31].
Mouse embryonic stem cells (E14) were cultured as describedpreviously [32]. Recombinant LIF was produced by CHO cells stably
expressing LIF (gift from Dr. Ichiro Taniuchi, RIKEN, Japan). 293T cells
were transfected using calcium phosphate precipitation as described
previously [31]. For small-scale transfection, Fugene HD reagent
(Roche, Mannheim, Germany) was used according to the manufac-
turer's protocol.
2.4. Immunoprecipitation and immunoblot analyses
Immunoprecipitation and immunoblot analyses were performed
as reported previously with somemodiﬁcations to detect endogenous
interaction between Hsp90β and TRIM8 [33]. In brief, ProteinA/G
sepharose beads were incubated with anti-TRIM8 antibody overnight
and then washed with 0.2 M phosphate (pH 8.0) followed by
crosslinking with 20 mM DMP at room temperature for 1 h. The
beads were washed with TBS and blocked with 5% skim milk at 4 °C
for 7 h. The beads were washed with lysis buffer and incubated with
E14 cell lysates at 4 °C overnight. Then the beads were washed again
with lysis buffer and boiled in SDS-PAGE sample buffer.
2.5. Antibodies
Antibodies against β-actin (0.2 μg/ml; AC15, Sigma), FLAG (1 μg/ml;
M2 and M5, Sigma), HA (1 μg/ml; HA.11, Covance, Berkeley, CA),
TRIM8 (1:1000 dilution, B01, Abnova, Taipei City, Taiwan), Nanog
(0.1 μg/ml; Abcam, Cambridge, MA), p53 (0.2 μg/ml; Pab240, Santa
Cruz Biotechnology, Santa Cruz, CA), Histone H2B (0.2 μg/ml; FL-126,
Santa Cruz), PARP (1:1000 dilution, 46D11, Cell Signaling, Danvers,
MA), Hsp90β (0.25 μg/ml; SMC-107A/B, StressMarq, Victoria, Canada),
PRMT1 (0.1 μg/ml; PRMT1-171, Santa Cruz), HP1α (0.5 μg/ml;
BMP001, MBL, Nagoya, Japan), Akt (1:1000 dilution, #9272, Cell
Signaling), STAT3 (1:1000 dilution, #9132, Cell Signaling), p-STAT3
(1:1000 dilution, #4113, Cell Signaling), and HDAC1 (1:1000 dilution,
#2062, Cell Signaling) were purchased from the indicated manufac-
turers. Rabbit anti-TRIM8 antibody was generated using recombinant
His6-TRIM8, which was puriﬁed from Escherichia coli by Ni-NTA
agarose (Invitrogen, Carlsbad, CA) in the presence of 8 M urea. Anti-
TRIM8 antibody was further puriﬁed by maltose binding protein
(MBP)-fused TRIM8 according to the protocol of the manufacturer
(New England BioLabs).
2.6. Retrovirus infection
Approximately 50% conﬂuent 293T cells in 60-mm dishes were
cotransfected with 1 μg pSUPER-retro-puro containing a nonfunc-
tional random sequence or TRIM8 sequences along with 1 μg
amphotrophic packaging plasmid pCL10A1 by the calcium phosphate
precipitation method. Media containing retrovirus were collected
48 h after transfection, and retroviral supernatant was added to E14
cells in 60-mm gelatinized dishes with 8 μg/ml polybrene (Sigma).
Cells were cultured in 5 μg/ml puromycin for 1 week following
retroviral transduction and resistant cells were pooled.
2.7. Quantitative PCR analysis
Total RNA was isolated from E14 cells with the use of an ISOGEN
(Nippon Gene, Tokyo, Japan), followed by reverse transcription (RT)
by ReverTra Ace (Toyobo, Osaka, Japan). The resulting cDNA was
subjected to real-time PCR with a StepOne machine and Power SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA). The
average threshold cycle (Ct) was determined from three independent
experiments and the level of gene expression relative to GAPDH was
determined. The primer sequences formouse TRIM8 and the promoter
region of Nanog were as follows: mouse TRIM8, 5′-AGAAGAACCT-
GAAGCTCACCAAC-3′ and 5′-GCAGGCAGACCTTCTGTG-3′; promoter
region #2, 5′-AGAGAGAGAGTGGTGTAAACAGTGGGTCTG-3′ and 5′-
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for promoter region #1 and Nanog were reported previously [34].
Primers for mouse p21, Noxa and GAPDH were reported previously
[32]. Primers for mouse Klf4, Sox2 and Oct3/4 were reported pre-
viously [28].
2.8. Chromatin immunoprecipitation (ChIP)
ChIP was performed as reported previously [35].
2.9. Subcellular fractionation of ES cell
Cytosolic, nuclear and detergent-insoluble fractionswere prepared
as reported previously [20].A
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Fig. 1. Expression of TRIM8 in undifferentiated ES cells. (A) Expression of endogenous TRIM8
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to immunoblotting with anti-TRIM8 (B01) antibody. Actin is shown as a loading control. (
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protocol, with TBS buffer containing 0.1% NP40. Bound proteins were
elutedwith 200 μg/ml FLAG peptide in TBS buffer containing 0.1% NP40,
followed by TCA precipitation and washing with cold acetone. Pre-
cipitateswere resolved by SDS-PAGE. Bandswere excised from gels, cut
into 1 mm pieces, washed in 100 mM ammonium bicarbonate, dried,
and digested overnight in sequencing grade modiﬁed trypsin (#V5111,
Promega). Peptideswere extracted using 0.1% triﬂuoroacetic acid (TFA)
in 0, 33 and 70% acetonitrile, combined and dried. Using a 1:1 dilution of
CHCA matrix (Applied Biosystems 4700 Proteomics Analyzer MassF
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Analyzer MALDI-TOF target plate (Applied Biosystems). One thousand
shots were ﬁred to acquire the initial MS spectrum, and intense peaks
were selected forMS/MS analysis. All MS/MS spectrawere processed by
aMASCOT distiller for generation of peak listﬁles andwere subjected to
a database search by the MASCOT algorithm (Matrix Science, London,
UK) against the non-redundant National Center for Biotechnology
Information (nrNCBI) database.
2.11. Electroporation
E14 cells (1×107) were suspended in 0.8 ml of PBS including a
plasmid (5 μg) in an electroporation cuvette and then electroporated
using aGene-Pulser II (Bio-Rad)under the conditionsof 300 Vand500 μF.
Cells were selected by treatment with puromycin (2 μg/ml) for 1 week.
2.12. Statistical analysis
Student's t test was used to determine the statistical signiﬁcance of
experimental data.D
G
C
0
F
A
0 22 45 0 22 45 0 22 45
IB: Hsp90
IB: Nanog
kD
95
43
Retinoic acid (h):
Knock-down:
Knock-down:
Co
nt
ro
l
#5#2
Co
nt
ro
l
shTRIM8
#5#2
Knock-down:
Co
nt
ro
l
shTRIM8
#5#2 Knock-down:
Knock-down:
R
el
at
iv
e 
m
R
N
A 
am
ou
nt
(N
an
og
)
R
el
at
iv
e 
m
R
N
A 
am
ou
nt
(K
lf4
)
R
el
at
iv
e 
m
R
N
A 
am
ou
nt
(S
ox
2)
R
el
at
iv
e 
m
R
N
A 
am
ou
nt
(p2
1)
p<0.001
p<0.0031.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
1.2
1.0
0.8
0.6
0.4
0.2
0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
Fig. 2. Selective inhibition of the transcription of Nanog by TRIM8. (A) Differentiation of ES
differentiated by retinoic acid (2.5 μM) for the indicated periods. Cell lysates were subjected
knock-down of TRIM8. ES cell lines were differentiated by retinoic acid (0.5 μM) for the indic
upregulation of Nanog by knock-down of TRIM8. Each cell line was subjected to quantitati
Statistical analysis of (D) p21, n=5, (E) Noxa, n=3 (F) Klf4, n=4 (G) Sox2, n=4 and (H)3. Results
3.1. Expression of TRIM8 in undifferentiated mouse ES cells
We previously checked around thirty different types of cell lines to
detect endogenous TRIM8 [20]. However, we failed to detect
endogenous TRIM8 in those cell lines. We then checked ES cells
because TRIM8 regulates PIAS3 and STAT3 is one of the regulators to
mediate the LIF-dependent signaling pathway [20,27]. Interestingly,
endogenous TRIM8 was detected in undifferentiated mouse ES cells
(Fig. 1A). Furthermore, differentiated ES cells cultured without LIF did
not express endogenous TRIM8, suggesting that the physiological
expression of TRIM8 is linked to maintenance of a pluripotent state of
ES cells. To study the roles of TRIM8 in ES cells, we knocked down
endogenous TRIM8 in ES cells. The expression levels of mRNA and
protein of TRIM8 were conﬁrmed by quantitative PCR (Fig. 1B) and
immunoblot analysis (Fig. 1C). We used several target sequences in
TRIM8mRNA for knock-down experiments and we found that #2 and
#5 shRNA were most efﬁcient. Knock-down of TRIM8 did not affect
colony formation of ES cells and the cells were able to be cultured forB
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Qualities of those cell lines were compared by deprivation of LIF and
quantify expression level of Nanog (Fig. 1E and F). The protein
amounts of Nanog in TRIM8 knocked-down ES cells showed almost
the same patterns as those in control cells after removal of LIF. These
ﬁndings indicated that TRIM8 is expressed in undifferentiated ES cells
but does not affect differentiation of ES cells by removal of LIF. We
previously reported that overexpressed TRIM8 was localized in the
nuclear-detergent insoluble fraction in HeLa cells [20]. We checked
whether endogenous TRIM8 also localizes in the nuclear-detergent-
insoluble fraction in ES cells. We fractionated ES cells into 1% Triton X-
100-soluble cytoplasmic and nuclear fractions as well as insoluble
fraction (Fig. 1G). Since only an upper band in the cytoplasmic frac-
tion of control cells was downregulated by knock-down of TRIM8,
endogenous TRIM8 is probably an upper band in detergent-soluble
cytoplasmic fraction in ES cells, suggesting that the effect of TRIM8
knockdown was approximately 60–70% (Fig. 1H). Interestingly,
different from HeLa cells, endogenous TRIM8 was expressed in the
detergent-soluble cytoplasmic fraction in ES cells.3.2. Selective inhibition of transcription of Nanog by TRIM8
Since it has been reported that Nanog is downregulated by retinoic
acid-induced differentiation [36], we checked the effect of knock-
down of TRIM8 on the down-regulation of Nanog by retinoic acid at
the protein level (Fig. 2A) and mRNA level (Fig. 2B). We found that
TRIM8 did not play a role in the differentiation of ES cells by retinoic
acid. However, we noticed that mRNA of Nanog was modestly but
signiﬁcantly upregulated by knock-down of TRIM8 (Fig. 2B and C).
Since it has been reported that ES cells express endogenous p53 and
that p53 prevents transcription of Nanog in ES cells [34], we also
checked expression levels of other p53-targeted genes, p21 and Noxa.
However, these genes were not affected by knock-down of TRIM8
(Fig. 2D and E). Actually, knock-down of TRIM8 did not change
sensitivity to DNA damage including damages caused by UV-
irradiation, cisplatin or etoposide (Fig. S1).DC
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To clarify the role of TRIM8 in ES cells, we puriﬁed a TRIM8
containing complex to identify binding proteins of TRIM8. Since we
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probably because of putative spontaneous differentiation of ES cells
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transfected 293T cells with ES cell lysates, followed by puriﬁcation
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Fig. 4. Regulation of nuclear translocation of STAT3 by TRIM8 and Hsp90β (A) Upregulation of phosphorylated STAT3 in the nucleus by knock-down of TRIM8. ES cell lines were
fractionated into cytosolic, nuclear and detergent-insoluble fractions, followed by immunoblotting with anti-phospho STAT3 (p-STAT3), STAT3, HDAC1, Hsp90β, Nanog, Actin or
HP1. LE, long exposure; SE, short exposure. (B) Statistical analysis of upregulation of phosphorylated STAT3 (p-STAT3) in the nucleus by knock-down of TRIM8 in ES cells. The
intensity of nuclear p-STAT3 shown in (A) was normalized by that of the corresponding HDAC1. The value of control cell line was deﬁned as 1. Data are means±SD of values from
three independent experiments. (C) Schematic representation of the promoter region of Nanog and locations of primer sets used to detect the promoter region. (D) Chromatin
immunoprecipitation (ChIP) assay with anti-STAT3 antibody. ES cell lines were lysed and utilized for ChIP assay. Immunoprecipitates were puriﬁed by phenol/chloroform extraction
and utilized for PCR to detect promoter region #1 of Nanog. Immunoprecipitates were also subjected to immunoblotting with anti-STAT3 antibody to show that the same amounts of
STAT3 were utilized for the CHIP assay. (E) Quantiﬁcation of the intensity of promoter region #1 in (D) co-puriﬁed by STAT3. (F) ChIP assay was performed using other primers.
Immunoprecipitates were puriﬁed by phenol/chloroform extraction and utilized for PCR to detect promoter region #2 of Nanog. (G) Quantiﬁcation of the intensity of promoter
region #2 in (F) co-puriﬁed by STAT3. (H) Downregulation of phosphorylation of STAT3 by an Hsp90-speciﬁc inhibitor. TRIM8 knocked-down ES cell lines as well as a control cell line
were treated with the Hsp90-speciﬁc inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG, 1 μM) for 8 h in the presence of LIF, followed by immunoblotting with anti-
phospho STAT3 (p-STAT3), STAT3, Nanog, Hsp90β or actin. Actin was used as a loading control.
1789F. Okumura et al. / Biochimica et Biophysica Acta 1813 (2011) 1784–1792(Fig. 4B). These ﬁndings suggest that knock-down of TRIM8 enhances
the increase in nuclear localization of phosphorylated STAT3. To
clarify the effect of phosphorylated STAT3(Y705) accumulated in the
nucleus, we performed a chromatin immunoprecipitation (ChIP)
assay (Fig. 4C–G). Mock or TRIM8 knocked-down cell lines were ﬁxed
with formaldehyde and lysed for immunoprecipitation with an anti-
STAT3 antibody. Genomic DNA was puriﬁed by chloroform/phenol
extraction and utilized for polymerase chain reaction (PCR), which
targeted the upstream region of the start codon of Nanog (Fig. 4C).Since it has been shown that p53 binds to the promoter region of
Nanog and inhibits transcription [34], we used the same primers
(Fig. 4C, #1) and found that STAT3 was able to interact with the
promoter region of Nanog (Fig. 4D). Although phosphorylated STAT3
(Y705) accumulated in TRIM8 knocked-down cell lines, we found that
binding of STAT3 to the promoter region of Nanogwas downregulated
by knock-down of TRIM8 (Fig. 4D and E). Furthermore, we utilized
independent cell lysates prepared on different days and different sets
of primers to eliminate technical errors, and we obtained the same
1790 F. Okumura et al. / Biochimica et Biophysica Acta 1813 (2011) 1784–1792results, suggesting that TRIM8 modulates the interaction between
STAT3 and the promoter region of Nanog (Fig. 4F and G). Hsp90β is a
molecular chaperone that functions as a major regulator of protein
conformation and plays a central role in protein homeostasis in the
cell. To clarify whether TRIM8 regulates phosphorylation of STAT3
through chaperone activity of Hsp90β, we treated TRIM8 knocked-
down ES cell lines as well as a control cell line with the Hsp90-speciﬁc
inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG),
which inhibits binding of ATP to Hsp90 (Fig. 4H). Phosphorylation
of STAT3 was reduced by 17-AAG treatment in all cell lines, indicating
that chaperone activity of Hsp90β was required for at least
maintenance of phosphorylation of STAT3. However, the expression
levels of Nanog, STAT3 and Hsp90β were not affected by 17-AAG
treatment. These ﬁndings suggest that TRIM8 modulates the STAT3A
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3.5. Differentiation of ES cells by overexpression of TRIM8
Since knock-down of TRIM8 upregulated transcription of Nanog
(Fig. 2C), we also analyzed ES cells in which FLAG–TRIM8(WT or
ΔRING) is constitutively overexpressed (Fig. 5A and B). Overexpres-
sion of FLAG–TRIM8(WT) or FLAG–TRIM8(ΔRING) caused disappear-
ance of Nanog (Fig. 5A). Furthermore, p-STAT3, STAT3 and Hsp90β
were downregulated in these cell lines (Fig. 5A). However, since
TRIM8(ΔRING) also caused decrease in the expression of these
proteins, this downregulation would not be regulated by ubiquitin–
proteasomal degradation involved in ubiquitin ligase activity ofB
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ession of TRIM8. ES cells were electroporated with a plasmid encoding FLAG–TRIM8(WT
l) for 1 week. Immunoblot analysis was performed with antibodies to Nanog, Hsp90β,
on gelatinized dishes in the presence of LIF for 2 days. Scale bar, 100 μm. (C) Model for
eterodimer, resulting in prevention of excessive signal transduction by STAT3. STAT3 at
on. A high concentration of phosphorylated STAT3may prevent binding to the promoter
1791F. Okumura et al. / Biochimica et Biophysica Acta 1813 (2011) 1784–1792TRIM8. Next, to examine whether TRIM8 maintains an undifferen-
tiated state of ES cells, we evaluated the morphological phenotype of
ES cells in which TRIM8 is overexpressed. We seeded each cell line on
dishes and cultured the cells with LIF for maintenance of pluripotency.
Colonies from control ES cells grew normally andwere enlarged in the
presence of LIF for 2 days, whereas TRIM8-overexpressing ES cells
differentiated into endoderm-like cells even in the presence of LIF
(Fig. 5B). These ﬁndings suggest that protein expression of TRIM8 is
tightly regulated at an appropriate level or that abnormal ES cells
spontaneously differentiate to be excluded from the pluripotent
population.
4. Discussion
In this present study, we showed that TRIM8 is expressed in
undifferentiated ES cells, suggesting that TRIM8 plays an important
role for maintaining pluripotency of ES cells. Although we knocked
down TRIM8 and established stable cell lines, these cell lines could
maintain pluripotency for at least several months. These ﬁndings
suggest that TRIM8 is one of the regulators in ES cells but not a crucial
regulator for maintaining pluripotency. Since ES cells lose pluripo-
tency in an inappropriate condition, they likely differentiate sponta-
neously and are excluded from the expanding pool as a safety system
to maintain the quality of ES cells. Therefore, knock-down of TRIM8
may cause the exclusion of differentiated or apoptotic ES cells from
experimental samples and, consequently, we may have not observed
an obvious biological effect of TRIM8 on ES cells.
Knock-down of TRIM8 modestly but signiﬁcantly upregulated
transcription of Nanog (Fig. 2), suggesting that TRIM8 controls the
expression of Nanog to maintain the expression at a constant level.
Other important transcription factors, including Klf4, Sox2 and Oct3/4,
were not affected by knock-down of TRIM8, suggesting that TRIM8
selectively affects the expression of Nanog. Although transcription of
Nanogwas upregulated, we did not detect upregulation of the protein
amount of Nanog. It has been reported that a high expression level of
Oct3/4, which is a master regulator of pluripotency and is required for
maintenance of an undifferentiated state, induces spontaneous
differentiation [37]. Hence, when protein expression of Nanog is
upregulated by knock-down of TRIM8, ES cells may differentiate and
be excluded from the culture pool.
To identify proteins that bind speciﬁcally to TRIM8 in ES cells, we
performed an in vitro binding assay combined with mass-spectro-
metrical analysis by using cell lysates from TRIM8-expressing 293T cells
and ES cells. We found that Hsp90β is one of the endogenous binding
partners to TRIM8. It has been reported that Hsp90β upregulates
nuclear translocation of STAT3 [30]. Therefore, we hypothesized that
TRIM8 affects nuclear translocation of Hsp90β/STAT3 complex
(Fig. 5C). A relatively large amount of phosphorylated STAT3 was
present in the nucleus with knock-down of TRIM8, but knock-down of
TRIM8 caused dissociation of STAT3 from the promoter region of Nanog
gene. It is important to clarify the molecular mechanisms for regulation
of the dissociation of STAT3 from the promoter region of Nanog in the
nucleus by TRIM8 and/or Hsp90β.
TRIM8 is a putative ubiquitin ligase because TRIM8 has a RING
domain, which interacts with E2 enzymes for the ubiquitination
cascade. Since Hsp90β seems to be a stable protein, TRIM8 may have
substrates other than Hsp90β. It is important to identify substrates in
ES cells to be ubiquitinated by TRIM8 followed by degradation by
proteasomes. Since TRIM8 expression is found only in undifferen-
tiated ES cells, the identiﬁcation of substrates of TRIM8 from ES cells is
critical for understanding the molecular mechanisms by which
pluripotency of ES cells is maintained.
Conventional human ES cells share multiple deﬁning features with
mouse epiblast stem cells (EpiSCs) rather than mouse ES cells [38].
Conventional human ES cells correspond, at least partially, to the
primed pluripotent state rather than to the naïve state of mouse ESCs,and LIF signaling does not seem to be important for maintenance.
However, conventional human ES cells and iPS cells were recently
converted to a more immature naïve pluripotent state by propagating
the cells in the presence of LIF andwith ectopic induction of Oct4, Klf4,
and Klf2 combined with inhibitors of glycogen synthase kinase 3β
(GSK3β) and mitogen-activated protein kinase (ERK1/2) pathway
[39]. It is important to determine whether TRIM8 is also involved in
the maintenance of naïve human ES cells to make them useful for
regenerative medicine.
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